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 21 
Abstract 22 
 23 
Does women’s body attractiveness predict indices of reproductive capacity? Prior 24 
research has provided evidence that large breast size and low waist-to-hip ratio (WHR) 25 
are positively associated with women’s estrogen and progesterone concentrations, but no 26 
previous studies appear to have directly tested whether ratings of women's body 27 
attractiveness are predicted by higher concentrations of ovarian hormones measured 28 
across broad regions of the menstrual cycle. Here, we collected daily saliva samples 29 
across 1-2 menstrual cycles from a sample of young women; assayed the samples for 30 
estradiol, progesterone, and testosterone; obtained anthropometric measurements of the 31 
women’s bodies; and also obtained attractiveness ratings of the women’s bodies from 32 
photographs of them taken in standardized clothing with faces obscured. Contrary to 33 
previous research, mean hormone concentrations were uncorrelated with breast size and 34 
WHR. Body mass index (BMI) was a very strong negative predictor of body 35 
attractiveness ratings, similar to previous findings. Zero-order associations between 36 
women’s mean hormone concentrations and mean attractiveness ratings were not 37 
significant; however, after controlling for BMI, attractiveness ratings were independently 38 
and positively associated with both estradiol and testosterone concentrations. Discussion 39 
focuses on the implications of these findings for whether attractiveness assessment 40 
mechanisms are specialized for the detection of cues of differential fecundity in young 41 
women’s bodies. 42 
43 
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 44 
1. Introduction  45 
 46 
 Functional approaches to understanding women’s body attractiveness posit the 47 
evolution of specialized mechanisms in perceivers that hone in on bodily features that 48 
would have predicted reproductively valuable qualities in human ancestral environments, 49 
such as health or fecundity (e.g., Gangestad & Scheyd, 2005; Symons, 1995). A low 50 
waist-to-hip ratio (WHR), for instance, has been proposed to signal qualities such as 51 
health, fecundity, and greater specialized fat stores for healthy fetal brain development 52 
(Lassek & Gaulin, 2008; Singh, 1993b; Singh & Singh, 2011), and, as such, men’s 53 
preference for this trait in mating partners (e.g., Furnham et al., 1997; Singh, 1993a; 54 
Streeter & McBurney, 2003) may provide an example of specialized preference 55 
mechanisms honing in on reproductively valuable traits in others. Complicating this 56 
issue, however, are findings from some non-Western cultures that suggest preferences for 57 
larger body size and associated higher WHRs in women (Marlowe & Wetsman, 2001; 58 
Wetsman & Marlowe, 1998; Yu & Shepard, 1998; c.f. Marlowe et al., 2005; Sugiyama, 59 
2004; Swami & Tovee, 2007); some have argued from such findings that preferences for 60 
traits such as low WHR are not products of specialized preference mechanisms but are 61 
instead attributable to Western media influences (Yu & Shepard, 1998).  62 
 63 
 One strategy for testing whether attractiveness judgments are generated by 64 
specialized preference mechanisms is to assess whether such judgments correlate with 65 
biological markers of health or fecundity, since positive correlations would be difficult to 66 
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explain if attractiveness standards were culturally arbitrary. Women’s concentrations of 67 
estradiol and progesterone appear to act as biological markers of fecundity given 68 
evidence that these concentrations are positively correlated with conception probabilities 69 
(see Baird et al., 1999; Lipson & Ellison, 1996; Venners et al., 2006). Jasienska et al. 70 
(2004) demonstrated that low WHR and large breast size predicted higher concentrations 71 
of these ovarian hormones across broad regions of the menstrual cycle, suggesting that 72 
these body shape characteristics may be valid cues of fecundity, at least within their 73 
sample of well-nourished Polish women. These authors did not report associations 74 
between hormone concentrations and ratings of the women’s body attractiveness, but 75 
such associations would more directly test whether preference mechanisms are attuned to 76 
physical cues of fecundity. Law Smith et al. (2006) reported that ratings of women’s 77 
facial attractiveness were positively correlated with the women’s late follicular estradiol 78 
concentrations (see also Puts et al., 2013), whereas Rilling et al. (2009) failed to find a 79 
significant correlation between ratings of women’s body attractiveness and a single 80 
measure of estradiol that did not control for cycle day. In summary, with respect to 81 
hormonal correlates of women’s body attractiveness, a single study has reported 82 
significant correlations between ovarian hormone concentrations and both WHR and 83 
breast size, but no previous study has tested for hormonal correlates of body 84 
attractiveness ratings when hormones were measured across broad regions of the 85 
menstrual cycle.  86 
 87 
 In the present research, we obtained salivary measurements of estradiol, 88 
progesterone, and testosterone across 1-2 menstrual cycles from a sample of young 89 
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women; collected ratings of the women’s body attractiveness from photos of them in 90 
standardized clothing (with faces obscured); and also obtained measurements of body 91 
mass index (BMI), breast size, and WHR. We hypothesized replication of higher 92 
estradiol and progesterone among women with lower WHR and larger breast size 93 
(Jasienska et al., 2004), and also predicted that concentrations of these hormones would 94 
positively predict body attractiveness ratings. Although not a primary purpose of the 95 
study, our data additionally allowed us to test for associations between body dimensions 96 
and attractiveness ratings, and here we expected replication of negative correlations (in 97 
Western cultures) between body attractiveness and both BMI and WHR (e.g., Rilling et 98 
al., 2009; Singh & Singh, 2011; Streeter & McBurney, 2003; Tovee & Cornelissen, 99 
2001). 100 
 101 
2. Methods 102 
 103 
2.1. Body stimuli 104 
 105 
2.1.1. Stimulus participants 106 
 107 
 Body photographs were obtained from a sample of women who participated in a 108 
larger study on the relationship between ovarian hormones and sexual psychology and 109 
behavior within natural menstrual cycles (see Roney & Simmons, 2013). Women 110 
participants provided daily saliva samples each morning across 1-2 menstrual cycles. 111 
Although 52 total women participated in the study, saliva samples were not sent for assay 112 
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for women with many missing samples, and hormone data were ultimately obtained for 113 
43 women; 41 of these women provided consent for use of their photographs in research. 114 
Of those women, 33 were judged to have experienced at least one ovulatory menstrual 115 
cycle (see below). These 33 women comprise the final stimulus sample (Mean age ± SD 116 
=  18.85 ± 1.28 years). Nineteen of the women self-identified as White, seven as Asian, 117 
five as Hispanic, and two as mixed ethnicity; none of the hormone variables, body 118 
dimensions, or attractiveness ratings differed significantly across ethnic categories.  119 
 120 
2.1.2. Anthropometry 121 
 122 
 Participants attended four laboratory sessions per menstrual cycle; anthropometric 123 
measurements were obtained in one of the sessions from the first cycle. Weight, muscle 124 
mass, body fat, visceral fat, and water percentage were measured using a Tanita electrical 125 
impedance scale (Tanita BC-573), and height was self-reported via questionnaire. The 126 
values for height and weight were used to calculate body mass index (BMI). Women 127 
research assistants used measuring tapes to measure breast size (the widest circumference 128 
at the level of the chest) and underbreast circumference; following Jasienska et al. (2004), 129 
the ratio of these two values was employed as a measure of relative breast size. WHR 130 
was measured from photographs of the women using Adobe Photoshop Elements 3.0; 131 
following a technique for photo measurements that was validated against direct body 132 
measurements (Steve Gaulin, personal communication, September 2012), the waist was 133 
defined as the narrowest point on the torso below the breasts, and the hips were defined 134 
as the widest point below the waist. Two research assistants independently measured 135 
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these and computed the ratio of the two; the means of the two ratios (r = 0.97) were used 136 
for data analyses.   137 
 138 
2.1.3. Hormone measures  139 
 140 
 Morning saliva samples were first stored in women’s home freezers and then 141 
delivered weekly to our research lab, after which they were stored at -80 C until shipping 142 
for assay (for full details of the collection procedure, see Roney & Simmons, 2013). We 143 
initially estimated the day of ovulation as 15 days prior to the end of each cycle, and sent 144 
for assay all samples in a nine day window centered on the estimated day of ovulation, as 145 
well as samples from alternating days outside of this window. Samples were shipped on 146 
dry ice to the Endocrine Core Laboratory at the California Regional Primate Research 147 
Center, Davis, CA, where they were assayed for concentrations of estradiol, testosterone, 148 
and progesterone. Full details of the assay procedures can be found in Roney & Simmons 149 
(2013); intra- and inter-assay CVs were below 10 percent for each of the hormones.  150 
 151 
Hormone data were used to re-estimate the day of ovulation based on the 152 
conjunction of the mid-cycle estradiol drop and the initiation of the luteal phase 153 
progesterone increase (for the specific algorithm, see Roney & Simmons, 2013). 154 
Following Jasienska et al. (2004), we computed cycle mean estradiol as the mean 155 
estradiol concentration for the 18 cycle days centered on the estimated day of ovulation, 156 
whereas cycle mean progesterone was computed as the average concentration of 157 
progesterone in the final 14 days of the cycle; although Jasienska et al. did not measure 158 
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testosterone, we computed cycle mean testosterone the same way as cycle mean estradiol 159 
(i.e. an average of the 18 cycle days centered on ovulation), given similarities in the 160 
secretion patterns of these hormones. Because identification of the day of ovulation was 161 
not possible in anovulatory cycles, we restricted data analyses to ovulatory cycles in 162 
order to ensure that similar cycle regions were being compared across women. Following 163 
Ellison et al. (1987), we defined as anovulatory any cycle that did not achieve a 164 
maximum progesterone value of at least 300 pmol/L.  165 
 166 
Among the 41 women with both photo consent and hormone data, eight did not 167 
experience an ovulatory cycle based on the above criterion. Among the remaining 168 
women, 18 had hormone data for two ovulatory cycles, 10 women participated in both 169 
cycles but only one of the two was judged ovulatory, and five women participated in a 170 
single cycle that was also judged ovulatory; as such, the final sample included hormone 171 
data from two cycles for 18 women and from one cycle for 15 women. Subject mean 172 
hormone concentrations were computed from a single cycle mean (as defined above) for 173 
the 15 women with one ovulatory cycle and as the average of the two cycle means for the 174 
18 women with two ovulatory cycles (this procedure entailed that some women had more 175 
reliable mean hormone values than others due to the larger number of sample days; 176 
however, a set of mixed regression models that treated daily hormone concentrations as 177 
dependent variables and body dimensions and attractiveness ratings as higher level 178 
predictor variables – and thereby weighted women with more hormone data more heavily 179 
due to the more reliable estimates of their hormone concentrations – produced identical 180 
statistical conclusions to those presented below using subject mean hormone values). 181 
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Data analyses tested associations between these subject mean hormone values and both 182 
body shape dimensions and mean body attractiveness ratings (see section 2.2.3).  183 
 184 
 185 
2.1.4. Stimulus photos 186 
 187 
 During one of the four laboratory sessions, each woman was photographed in 188 
standardized dress comprised of grey gym shorts and a blue tank top shirt. Photos were 189 
taken with a digital camera at a standard distance in a windowless room with artificial 190 
lighting. For each woman, photos were taken from front-facing, back-facing, and side-191 
facing perspectives; these three photos were placed together onto a single stimulus array 192 
for each woman, with an opaque mask blocking the head area in each photo. An example 193 
stimulus array appears in Fig. 1.  194 
 195 
2.2. Stimulus ratings 196 
 197 
2.2.1. Rating participants  198 
 199 
Raters were UCSB students who participated in exchange for partial course credit.  200 
The primary 39 raters were 23 men (Mean age ± SD = 19.17 ± 1.50 years) and 16 women 201 
(Mean age ± SD = 18.81 ± 1.22 years), but an additional batch of 19 raters comprised of 202 
11 women (Mean age ± SD = 19.64 ± 0.67 years) and 8 men (Mean age ± SD= 19.38 ± 203 
1.30 years) was recruited in order to obtain ratings for five stimulus photos that were 204 
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previously omitted due to a clerical error. Participants provided written, informed consent 205 
for their participation, and all procedures were approved by the UCSB Institutional 206 
Review Board.  207 
 208 
2.2.2. Rating procedures 209 
 210 
Raters viewed the stimulus photos one at a time on a computer and were asked to 211 
indicate how physically attractive each woman was, relative to other women of the same 212 
age, on a 1-7 likert-type scale. After rating all of the stimuli for general attractiveness, 213 
participants rated them for attractiveness “as a SHORT-TERM partner” and for 214 
attractiveness “as a LONG-TERM partner,” with the order of these ratings 215 
counterbalanced across raters; the order of photo presentation was randomized within 216 
each rating dimension.  217 
 218 
There was high between-rater agreement for each of the three rating dimensions 219 
(all ICCs > 0.90); thus, ratings were aggregated across raters to give each woman a mean 220 
rating for each rating dimension. The three rating dimensions also had high reliability (α 221 
= 0.99 for the mean ratings) and were therefore averaged to create a composite 222 
attractiveness variable that was used in subsequent data analyses. Male and female raters 223 
were in high agreement regarding their perceptions of the women’s attractiveness (ICC = 224 
0.92 for the composite mean attractiveness ratings). The average attractiveness rating was 225 
just below the midpoint of scale (composite attractiveness mean = 3.92, S.D. = 1.05). 226 
 227 
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2.2.3. Data analyses 228 
 229 
 Pearson correlation, partial correlation, and multiple regression were employed to 230 
test relationships between women’s mean hormone concentrations (as defined in 2.1.3), 231 
body dimensions, and rated attractiveness. Following Jasienska et al. (2004), we also 232 
constructed categorical body dimension groups (top vs. bottom quartile of WHR and 233 
breast size, as well as combinations of above and below average WHR with above and 234 
below average breast  sizes) and t-tests and one-way ANOVAs were used to test whether 235 
such groups differed in mean hormone concentrations. Bias-corrected, nonparametric 236 
bootstrapping procedures (see Preacher & Hayes, 2008) were employed as tests of 237 
whether specific body dimensions statistically mediated relationships between hormone 238 
concentrations and attractiveness ratings. This analysis essentially tests whether a third 239 
variable is related to both the hormones and attractiveness ratings such that its addition to 240 
the model significantly diminishes the direct effect of hormones on attractiveness ratings; 241 
mediation is established if the 95% confidence interval for the unstandardized indirect 242 
effect does not include zero. 243 
 244 
 Measured variables more than three standard deviations from their respective 245 
means were excluded to avoid undue influence of outliers; one subject mean testosterone 246 
concentration and one BMI value were thus excluded (effect sizes for significant effects 247 
were generally larger with the outliers included). After outlier removal, all mean hormone 248 
and body dimension variables were approximately normally distributed by visual 249 
inspection and the Shapiro-Wilk test.   250 
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 251 
3. Results 252 
 253 
3.1. Hormones 254 
 255 
Excluding the one woman whose mean testosterone concentration was an outlier, 256 
the 32 women in the sample provided 798 saliva samples from the middle 18 days of 257 
their respective cycles out of 900 eligible cycle days (89% compliance rate). After 258 
selection of saliva samples from alternating days outside of the nine day window 259 
surrounding the initial estimate of mid-cycle, measured hormone concentrations were 260 
available for 565 and 577 of these days for estradiol and testosterone, respectively 261 
(insufficient remaining quantity of saliva for assay accounted for the difference given that 262 
testosterone was assayed first). With respect to the final 14 days of the cycle, 631 saliva 263 
samples were collected out of 700 eligible cycle days (90% compliance rate); 264 
progesterone assay values were obtained for 388 of these days. Mean hormone 265 
concentrations aggregated across women and aligned against day of the cycle reproduced 266 
prototypical hormone curves in this sample (see Fig. 1 in Roney & Simmons, 2013), thus 267 
providing evidence for the validity of the hormone assays.  268 
   269 
3.2. Hormones and body dimensions 270 
 271 
Table 1 presents correlations between mean hormone concentrations, body 272 
dimensions, and body attractiveness ratings. Contrary to previous findings (Jasienska et 273 
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al, 2004), there were null zero-order correlations between body dimensions and 274 
hormones; neither WHR nor breast size was significantly associated with mean estradiol, 275 
progesterone, or testosterone. Null results persisted in one-way ANOVAs that tested for 276 
differences in mean hormone concentrations across the four body shape categories (large 277 
and small WHR crossed with large and small breast size) defined by Jasienska et al. 278 
(2004) (all ps > 0.45). Likewise, a series of t-tests found no differences in mean 279 
hormones when comparing women in the top and bottom quartiles of breast size and 280 
WHR, respectively (all ps > 0.25).  281 
 282 
3.3. Predictors of body attractiveness ratings 283 
 284 
3.3.1. Morphological predictors 285 
 286 
Consistent with previous research, body attractiveness was significantly 287 
negatively associated with both WHR and BMI (see Table 1). A multiple regression with 288 
WHR and BMI entered together as predictors of body attractiveness ratings revealed a 289 
strong independent effect of BMI (β = -0.78, p < 0.001) and a null effect of WHR (β = -290 
0.03, p = 0.82). BMI accounted for approximately 63% of the variance in women’s body 291 
attractiveness. 292 
 293 
3.3.2. Hormonal predictors 294 
 295 
As can be seen from Table 1, there were no significant zero-order correlations 296 
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between subject mean hormone concentrations and body attractiveness ratings, although 297 
power limitations may have prevented detection of a small association between estradiol 298 
and attractiveness (r = 0.24). The large association between BMI and attractiveness may 299 
have obscured the influence of smaller predictor variables, however, and we therefore 300 
tested whether hormone concentrations were correlated with attractiveness ratings after 301 
controlling for the influence of BMI. Table 2 demonstrates that subject mean estradiol 302 
and testosterone both exhibited significant partial correlations with body attractiveness 303 
ratings after controlling for BMI. Progesterone was not a significant independent 304 
predictor of the body attractiveness residuals from BMI, and neither WHR nor breast size 305 
had residual variance from BMI that was significantly associated with any hormone. A 306 
multiple regression analysis testing the partial effects of BMI, testosterone, and estradiol 307 
revealed independent effects of BMI (β = -0.83, p < 0.001), mean estradiol (β = 0.20, p = 308 
0.05), and mean testosterone (β = 0.22, p = 0.04); the two hormones jointly explained an 309 
additional 10% of the variance in body attractiveness beyond that explained by BMI 310 
alone (change in R
2
 F (2, 27) = 5.55, p = 0.01).  311 
 312 
Given that the estradiol and testosterone measurements represented subject means 313 
for 18 days surrounding ovulation, it is possible that their associations with body 314 
attractiveness could have been driven by effects in a narrow region of the cycle. To assess 315 
this, Fig. 2 plots hormone concentrations against day of the cycle (aligned on the 316 
estimated day of ovulation as day zero) with separate curves for women who were above 317 
and below the mean residual attractiveness rating after controlling for BMI. It can be seen 318 
that estradiol was consistently higher across the entire cycle among women who were 319 
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rated more attractive than predicted by their BMI alone (Fig. 2A); this pattern was less 320 
consistent for testosterone, but still visible across broad regions of the cycle (Fig. 2B); 321 
whereas the curves were very similar across the entire cycle for progesterone (Fig. 2C).  322 
 323 
The patterns depicted in Fig. 2 suggest that, after controlling for BMI, other 324 
observable cues in women’s bodies both contribute to attractiveness judgments and 325 
predict concentrations of estradiol and testosterone. In an exploratory attempt to identify 326 
such cues, we employed nonparametric bootstrapping methods to first test whether scale 327 
measures of women’s muscle mass, visceral fat, body fat, or water percentage were 328 
significant mediators between either estradiol or testosterone and women’s body 329 
attractiveness, controlling for BMI. None of these variables significantly mediated the 330 
relationship between either of the hormones and attractiveness ratings, whether the 331 
mediators were tested separately or jointly (all CIs for the indirect effects included zero). 332 
Based on the subjective impression that women with higher residual attractiveness ratings 333 
had waists that angled inward more sharply from their upper torsos, we also computed a 334 
ratio of shoulder width (measured from front-facing photos) to waist width and tested it 335 
as a mediator of the hormone effects. This shoulder-to-waist (SWR) ratio was in fact a 336 
significant mediator between residual variance in women’s body attractiveness from BMI 337 
and both their estradiol (Indirect Effect = 0.117, SE = 0.078, 95% CI = 0.015 - 0.402) and 338 
testosterone (Indirect Effect = 0.018, SE = 0.01, 95% CI = 0.004 – 0.05) concentrations, 339 
with larger SWR associated with both higher hormone concentrations and greater 340 
attractiveness. Neither shoulder width nor waist width on its own was a significant 341 
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mediator of the relationship between hormone concentrations and residual attractiveness 342 
ratings (all CIs included 0). 343 
 344 
4. Discussion 345 
 346 
4.1. Hormones, body dimensions, and body attractiveness 347 
 348 
The present research provided an initial, direct test of the possible relationship 349 
between women’s body attractiveness and their ovarian hormone production across broad 350 
regions of the menstrual cycle. Contrary to our predictions, there were no significant 351 
zero-order correlations between hormone concentrations and attractiveness ratings. 352 
However, after controlling for BMI, which was strongly negatively associated with 353 
attractiveness, women’s concentrations of estradiol and testosterone were significantly 354 
positively correlated with ratings of their body attractiveness. As can be seen from Fig. 2, 355 
furthermore, these relationships held across broad regions of the menstrual cycle. These 356 
patterns thus provide some evidence that perceivers’ attractiveness judgments may in fact 357 
hone in on cues of fecundity in young women’s bodies, although interpretive questions 358 
are raised by the necessity of holding BMI constant in order to demonstrate robust 359 
relationships between hormones and attractiveness (see discussion of this issue in section 360 
4.2 below).   361 
 362 
 Given previous research demonstrating higher estradiol and progesterone among 363 
women with lower WHR and larger breast size (Jasienska et al., 2004), WHR and breast 364 
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size were expected to mediate any relationship between body attractiveness and hormone 365 
concentrations. However, there was no evidence for this in our study. Neither breast size 366 
nor WHR were associated with subject mean concentrations of estradiol, progesterone, or 367 
testosterone; nor did they predict any hormone after controlling for variability in these 368 
body shapes due to BMI. Thus, our results failed to replicate the pattern of associations 369 
between body shapes and hormone concentrations demonstrated by Jasienska et al. 370 
(2004).  371 
 372 
Differences in the study samples may help account for inconsistencies between 373 
results of the current study and that of Jasienska et al. (2004). Whereas Jasienska et al. 374 
(2004) investigated over a hundred Polish women (mean age = 29 years), our sample was 375 
younger (mean age = 18 years), more ethnically heterogeneous, and much smaller. 376 
Menstrual cycles are notably less stable in young women (Metcall & Mackenzie, 1980) 377 
and may vary across cultural groups (Vitzthum, 2009), although ethnicity was not 378 
associated with any variables examined in the present study and data were analyzed only 379 
from cycles that were confirmed to be ovulatory. Nonetheless, age differences between 380 
the samples still provide a plausible explanation for the different findings, and the current 381 
results suggest that the hormone-body shape relationships reported by Jasienska et al. 382 
(2004) may not generalize to younger samples of women. Although our sample size was 383 
less than ideal, low power is unlikely to explain the null relationships between hormones, 384 
WHR, and breast size given the absence of even trend-level effects in the relevant 385 
analyses (see Table 1). Furthermore, our sample size was sufficient to detect relationships 386 
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between estradiol, testosterone, and residual variance in body attractiveness not 387 
accounted for by BMI.   388 
 389 
 The lack of relationships between hormone concentrations and either WHR or 390 
breast size suggested that at least one other physical cue was mediating the relationship 391 
between both estradiol and testosterone and the body attractiveness residuals from BMI. 392 
Exploratory analyses revealed the shoulder-to-waist ratio (SWR) as a statistical mediator 393 
of the effects of both estradiol and testosterone on attractiveness ratings. These results 394 
should be interpreted with caution, however, given both the number of potential 395 
mediators tested (see section 3.3.2) and the fact that we had no way of testing whether 396 
observers actually used this ratio as a perceptual cue that contributed to their 397 
attractiveness judgments. SWR might correlate inversely with android fat depositions 398 
(i.e. fat in the abdomen and upper torso) since such fat will cause the waist to spread out 399 
toward the width of the shoulders and thus reduce this ratio (WHR may not capture quite 400 
the same variable given cases of wide waists but even wider hips); android fat deposits, in 401 
turn, have been shown to be strong negative predictors of body attractiveness ratings 402 
(e.g., Faries & Bartholomew, 2012; Rilling et al., 2009). Ideally, android fat would be 403 
measured more directly via tools such as dual-energy X-ray absorptiometry scans (see 404 
Faries & Bartholomew, 2012; Sowers et al., 2001), and future research that combined 405 
such measurements with hormone assays would allow for more precise tests of which 406 
body dimensions may account for relationships between endocrine variables and body 407 
attractiveness ratings.  408 
  409 
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4.2. BMI, hormone concentrations, and specialized preference mechanisms  410 
 411 
 Why was it necessary to control for BMI in order to see clear relationships 412 
between ovarian hormone concentrations and body attractiveness ratings? If specialized 413 
preference mechanisms track cues of fecundity as indexed by hormone concentrations, 414 
then one might expect positive zero-order associations between hormones and 415 
attractiveness without the need to control for other variables. We offer two conjectures 416 
regarding this issue.   417 
 418 
 First, BMI may predict other fitness-relevant traits aside from fecundity that are 419 
also relevant to attractiveness judgments. Higher BMI is strongly predictive of a wide 420 
array of health problems in industrialized countries (e.g., Calle et al., 2003; Gilmore, 421 
1999; Manson et al., 1995; Willett et al., 1995). Although many of those health problems 422 
may not have been relevant to reproductive fitness in ancestral environments, higher BMI 423 
has also been associated with greater fluctuating asymmetry (Hume & Montgomerie, 424 
2001; Losken et al., 2005; Manning, 1995; Milne et al., 2003) and higher rates of 425 
inflammation (e.g. Festa et al., 2001; Panagiotakos et al., 2005; Trayhurn & Wood, 426 
2005), suggesting that greater BMI may predict greater developmental instability and 427 
reduced immunocompetence, both of which likely entailed fitness costs to mates even 428 
independent of any effects on fecundity. These inverse associations of BMI with health 429 
and developmental stability – at least in industrialized nations – may lead cues of high 430 
BMI to become associated with poor health, thus partly explaining the negative effect of 431 
BMI on attractiveness. In addition, BMI is on average positively correlated with age in 432 
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the United States (Brown et al., 1992; Fryar et al., 2013; Lassek & Gaulin, 2006), such 433 
that high BMI may become a cue associated with declining reproductive value (Wells, 434 
2010). These associations of BMI with health and age appear to be reversed under 435 
conditions of food shortage (e.g., women’s BMI is known to decline with age in many 436 
subsistence societies; see Jelliffe & Maddocks, 1964; Little et al., 1992; Shell-Duncan & 437 
Yung, 2004; Tracer, 1991; also, BMI positively indexes health in societies where the 438 
range of BMI is overall lower; see Hosegood & Campbell, 2003; Pierce et al., 2010), and 439 
thus preference mechanisms that track cues of health and reproductive value may produce 440 
opposite associations between BMI and attractiveness in regions with food surplus vs. in 441 
regions with chronic nutritional stress (see Swami & Tovee, 2007; Wells, 2010). Whether 442 
such BMI preferences reflect learned associations between cues of health or age and 443 
BMI, or are the output of cognitive mechanisms that assess the reliability of food supply 444 
over ontogeny and adjust BMI preferences accordingly, is unknown. Regardless, BMI 445 
could act as a cue of health and age that has such large effects on attractiveness ratings 446 
that it swamps the smaller effects on attractiveness of cues associated with ovarian 447 
hormone production; once BMI is held constant, however, cues of hormone 448 
concentrations emerge as significant predictors of attractiveness. On this account, 449 
specialized perceptual mechanisms do in fact track cues of fecundity, but these cues have 450 
smaller effects on attractiveness judgments than do cues associated with BMI.  451 
 452 
 Second, correlations between attractiveness ratings and salivary measures of 453 
hormone concentrations may be partially obscured by associations between BMI and sex 454 
hormone binding globulin (SHBG). SHBG binds to both estradiol and testosterone and 455 
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higher SHBG concentrations reduce the free, bioavailable concentrations of these 456 
hormones that are measured in salivary assays (Ellison,1988). Higher BMI very strongly 457 
and consistently predicts lower SHBG (e.g., Bruning et al., 1992; Dorgan et al., 1995; 458 
Thomas et al., 1997; Turcato et al., 1997; Tworoger et al., 2006; for a review, see 459 
Morisset et al., 2008), and experimentally induced weight loss can produce doubling of 460 
SHBG concentrations (with associated drops in free but not total hormone 461 
concentrations) in as little as two weeks (e.g., Kiddy et al., 1989, 1992; Turcato et al., 462 
1997; for a review, see Morisset et al., 2008). These patterns suggest that higher BMI is 463 
likely to be associated with artificially inflated measures of salivary, free hormones 464 
relative to the total ovarian hormone production; consistent with this, in a large study of 465 
premenopausal women, BMI was significantly inversely correlated with total estradiol 466 
but was uncorrelated with free estradiol (Tworoger et al., 2006). This in turn implies that 467 
when two women have the same free hormone concentrations but differ in BMI, the 468 
woman with lower BMI is likely to have greater ovarian hormone production since a 469 
greater fraction of her hormones will be bound to SHBG. Likewise, when two women 470 
have the same BMI but differ in free hormone concentrations, the woman with greater 471 
free hormone concentrations should have higher ovarian production since the effect of 472 
BMI on SHBG will be held constant. As such, if perceivers’ attractiveness judgments 473 
specifically track cues of ovarian hormone production, then BMI should negatively 474 
predict attractiveness when free hormones are held constant and free hormones should 475 
positively predict attractiveness when BMI is held constant, which is exactly the pattern 476 
produced by the regression models in section 3.3.2. In short, controlling for BMI may 477 
increase the size of correlations between free hormone concentrations and attractiveness 478 
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ratings by removing the variability in hormone concentrations that is associated with 479 
binding proteins and is thus potentially unrelated to fecundity. This idea could be tested 480 
more directly in future research that used blood samples in order to test associations 481 
between body attractiveness and both total and free hormone concentrations.   482 
 483 
4.3. Independent effects of testosterone on attractiveness 484 
 485 
 The positive effect of testosterone on attractiveness after controlling for BMI was 486 
surprising given evidence that elevated testosterone in women may promote visceral fat 487 
deposition (e.g., Evans et al., 1983; Sowers et al., 2001) and be associated with reduced 488 
fecundity (e.g., Okon et al., 1998; Steinberger et al., 1979). Many of the negative effects 489 
of testosterone on reproductive functioning are associated with obesity (Clark et al., 490 
1995; Kiddy et al., 1992; Pasquali et al., 1997) and associated reductions in SHBG (see 491 
above), however, such that controlling for BMI may more uniquely capture follicle-492 
derived sources of testosterone that could in principle be associated with higher 493 
fecundity. Testosterone acts a precursor to estradiol produced by the dominant follicle, 494 
for instance, and peri-ovulatory peaks in estradiol are typically accompanied by 495 
concomitant peaks in testosterone (e.g., Abraham, 1974; Campbell & Ellison, 1992; 496 
Roney & Simmons, 2013) such that larger dominant follicles that produce higher 497 
estradiol in more fertile cycles may likewise produce higher testosterone. As such, the 498 
combination of estradiol and testosterone concentrations may better predict dominant 499 
follicle production within ovulatory cycles than does the concentration of either hormone 500 
alone, thus potentially explaining the independent effects of the two hormones on 501 
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attractiveness ratings. This is speculation, of course, and the unexpected association of 502 
attractiveness with testosterone concentrations warrants replication before assigning 503 
much confidence to the robustness of this finding.  504 
 505 
4.4. Conclusion 506 
 507 
 The present study is to our knowledge the first to demonstrate a link between 508 
women’s body attractiveness and concentrations of ovarian hormones measured across 509 
broad regions of the menstrual cycle. Both estradiol and testosterone independently 510 
predicted body attractiveness ratings after controlling for the effects of BMI, which 511 
suggests that preference mechanisms may indeed track cues of fecundity in young 512 
women’s bodies. The evidence for specialized attractiveness assessment mechanisms 513 
could be substantially strengthened via cross-cultural demonstrations of relationships 514 
between hormones and attractiveness across diverse ecological and social conditions, 515 
however, and tests of such relationships therefore represent an important direction for 516 
future research.    517 
 518 
519 
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Figure Legends 730 
 731 
Figure 1. Sample stimulus photo. 732 
 733 
Figure 2. Mean salivary estradiol (A), testosterone (B), and progesterone (C) aligned 734 
against estimated day of cycle (day 0 represents the estimated day of ovulation) for below 735 
and above average attractiveness residuals from BMI.  Error bars represent SE. 736 
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